Recruiting

N1 System & R1 Robot

Sponsor:

Neuralink Corp

Code:

NCT07929792

Conditions

Spinal Cord Injury

Amyotrophic Lateral Sclerosis

Chronic Ischemic Stroke

Tetraplegia/Tetraparesis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

N1 Implant

R1 Robot

Study Details

Brief summary:

The purpose of this study is to evaluate the safety and preliminary effectiveness of the N1 System, a fully implanted brain-computer interface placed in the motor cortex with the R1 Robot. The study builds on knowledge gained in a previous clinical investigation of this system. It enrolls adults with severe upper-limb impairment from spinal cord injury, amyotrophic lateral sclerosis (ALS), or chronic ischemic stroke. Participants use neural signals recorded by the N1 Implant to control a computer cursor or virtual keyboard. The study will describe serious adverse device effects and will assess digital daily activities, computer-control performance, independent use of the system, and participant-, clinician-, and caregiver-reported outcomes. Up to 10 participants will be enrolled at up to five sites in the United States and followed for about 2 years after implantation, or about 3 years if they choose extended follow-up. There is no comparison group; each participant's results are compared with their own baseline.

Conditions

Spinal Cord Injury

Amyotrophic Lateral Sclerosis

Chronic Ischemic Stroke

Tetraplegia/Tetraparesis

Study ID

NCT07929792

Start date

Nov, 2026

Status verified date

Nov, 2026

Completion date

Nov, 2031

Anticipated

Primary completion date

Nov, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

● A diagnosis of: (A) Spinal cord injury (SCI) for at least 12 months with a muscle power grade of ≤ 3/5 in all muscles of the arms and hands principally innervated by C6-T1 nerve roots at the time of screening AND the Investigator confirms that bilateral upper-limb weakness prevents reliable, independent use of standard digital-access devices. OR (B) Amyotrophic lateral sclerosis (ALS) with

1. Muscle power grade ≤4/5 at C5 in both arms; AND
2. Muscle power grade ≤3/5 in all muscles of both arms and hands principally innervated by C6-T1 nerve roots, except that strength above 3/5 in individual C6-T1 muscle groups is permitted if both of the following are met:

1. ALSFRS-R Item 4 (Handwriting) score ≤2; AND
2. The Investigator confirms that bilateral upper-limb weakness prevents reliable, independent use of standard digital-access devices. OR (C) Chronic ischemic stroke, with the event occurring at least 12 months before screening, resulting in residual hemiparesis of the pre-morbid dominant upper extremity, with a completion time on the Nine-Hole Peg Test (9-HPT), per standardized protocol, that exceeds 3 standard deviations above the respective established age- and hand-specific normative mean completion times for both hands.

  • Age ≥ 18 years.
  • Stable medical, physical, and psychological condition as considered by the investigators.
  • Ability to communicate verbally or with the use of a computer or communication aid.
  • Willingness to comply with all study procedures and availability for the duration of the study.
  • If the participant requires daily continuous support from a personal caregiver, the presence of a caregiver throughout the study is mandatory.
  • Willingness and ability of a caregiver to monitor the participant for medical complications and behavioral changes, and respond to alerts regarding device function.
  • Presence of or willingness to acquire reliable internet.\*
  • Willing and able to provide informed consent. \*Sponsor will reimburse participants for the cost of reasonable high-speed internet as needed during participation in the study

Exclusion Criteria:
  • ● History of poorly controlled seizures or epilepsy.

  • History of poorly controlled autonomic dysreflexia.
  • Morbid obesity (Body Mass Index > 40).
  • Current deep venous thrombosis or pulmonary embolism.
  • Diagnosis of acute myocardial infarction or cardiac arrest within the last 12 months.
  • Requires magnetic resonance imaging (MRI) for any ongoing medical conditions within the next year
  • Any implanted, or previously explanted, intracranial device, except where:

1. the device is a marketed intracranial stent or other endovascular implant that is labeled MR Conditional, and the Neurosurgeon confirms during preoperative surgical planning that its location is compatible with the planned craniectomy and thread insertion trajectory; or
2. the explanted device was not previously implanted in the same hemisphere as the hemisphere of interest for the implantation of the N1 Implant
  • Any active implanted devices including but not limited to cardiac pacemakers, cardiac defibrillators, diaphragmatic pacemakers, peripheral or central nerve stimulators\*.
  • Currently receiving or may receive transcranial magnetic stimulation therapy, diathermy, electroconvulsive therapy, or transcranial ultrasound within the next year.
  • Pregnant or of child-bearing potential and not using or planning to use contraception during the period of study participation.
  • Presence of mild or greater cognitive impairment per neuropsychological assessments.
  • Psychotic illness or chronic psychiatric disorder, or major depression if untreated (Diagnosis of Axis I or Axis II).
  • Contraindication for preoperative MRI.
  • Preoperative brain MRI demonstrating hemorrhage, tumor, distorted or adverse anatomy.
  • History of gadolinium contrast allergy.
  • Any type of destruction and/or damage to the primary motor cortex region as determined by MRI.
  • Are blind.
  • Ongoing use of anticoagulant or antiplatelet medication that cannot be suspended perioperatively.
  • Receiving invasive mechanical ventilation without a tracheostomy that has been in place for at least 3 months, or without stable ventilator settings for at least 1 month prior to enrollment.
  • May require invasive mechanical ventilation within the next year, and does not intend to undergo tracheostomy or placement of a percutaneous endoscopic gastrostomy (PEG) tube if invasive ventilation becomes necessary.
  • Currently participating in an investigational study (device and/or pharmaceutical) within 30 days prior to entering this study, or such investigational treatment planned during the 24 months following enrollment, unless approved by Sponsor.
  • Anatomical or functional characteristics of the skull, meninges, and brain incompatible with the surgical approach and N1 Implant, as assessed by

MRI or CT, specifically:
  • Outer skull-to-pia distance < 5.4 mm over region of interest.
  • Scalp thickness < 3 or > 20 mm over region of interest.
  • Imaging evidence of stroke in the planned implant cortical target (for stroke patient population).
  • Any condition, including serious co-morbidities such as major organ failure, which in the opinion of the Investigator, would compromise the participant's ability to safely participate in the study or undergo the implantation procedure. \*Intrathecal baclofen pumps are exempt from this criterion.

Study Design

Enrollment

10 participants

Anticipated

Intervention Model

Single group

Primary purpose

Device Feasibility

Interventions and Outcome Measures

Arms

experimental: Neuralink N1 Implant and R1 Robot

Implantation of the N1 Implant by the R1 Robot.

Interventions

N1 Implant

The N1 Implant is a type of implantable brain-computer interface

R1 Robot

The R1 Robot is a robotic electrode thread inserter that implants the N1 Implant.

Primary outcome measure

  • Serious adverse device effects (SADEs) [ Time Frame: From surgical implantation day ("Day 0") through the 90-day follow-up visit. ]

Central Contacts and Locations

Central contacts

Locations

University of Miami

Recruiting

Miami, Florida, United States, 33136

Contacts

Principal Investigator:

Jonathan Jagid, MD

More Information

Sponsor

Neuralink Corp

Last update posted

Nov 10, 2026

Last verified

Nov, 2026

Keywords

  • spinal cord injury
  • SCI
  • BCI
  • brain computer interface
  • ALS
  • quadriplegia
  • tetraplegic
  • paralysis
  • stroke
  • chronic ischemic stroke

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-11. This information was provided to ClinicalTrials.gov by Neuralink Corp on 2026-11-10. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.